•  
  •  
  •  
  •  

2026-02-19 19:56:56

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Steelco Gujarat Launches ₹14.9 Cr Rights Issue
  • INOXGFL Group Companies Emerge as Successful Bidders For Wind World India's IPP and O&M Arms
  • Embraer and Mahindra Group Advance Localization Strategy in India with Planned C-390 Millennium MRO Capability
  • Hemant Surgical Bags ₹264 Cr Medical Equipment Order from Govt
  • LTM Partners with Indian Institute of Creative Technologies to build India's NextGeneration Creative Technology Talent Pipeline

Keywords Selected:  USFDA

Stock Report

  • Alembic Pharmaceuticals Ltd receives 2 observations for Karakhadi Injectable Facility
  • Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg
  • USFDA inspection at the manufacturing facility of Enzene Biosciences Limited
  • Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
  • Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of Sickle Cell Disease
  • Zydus receives tentative approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Lord's Mark Industries Ltd achieves significant milestone
  • Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
  • Granules Pharmaceuticals Inc. receives FDA tentative approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets
  • Biocon Ltd receives EIR from USFDA with VAI status for Cranbury facility
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004%
  • APL Healthcare Ltd's Unit-4 gets 5 observations from USFDA
  • US FDA determines Sun Pharma's Baska facility inspection classification as OAI
  • Lupin receives EIR from US FDA for its Nagpur Injectable Facility
  • Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission
  • Successful completion of USFDA inspection at Vizag facility
  • Apitoria Pharma Pvt Ltd receives 3 observations from USFDA for Unit-V
  • Granules Life Sciences Pvt Ltd facility receives EIR from USFDA
  • Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%
  • Caplin Steriles gets USFDA approval for Linezolid Injection, Infusion bags
  • Caplin Steriles granted final approval by USFDA for Acetaminophen Injection, infusion bags
  • Ipca Laboratories Ltd receives 3 observations from USFDA for API facility at Tarapur

Latest Post

  • Steelco Gujarat Launches ₹14.9 Cr Rights Issue
  • INOXGFL Group Companies Emerge as Successful Bidders For Wind World India's IPP and O&M Arms
  • Embraer and Mahindra Group Advance Localization Strategy in India with Planned C-390 Millennium MRO Capability
  • Hemant Surgical Bags ₹264 Cr Medical Equipment Order from Govt
  • LTM Partners with Indian Institute of Creative Technologies to build India's NextGeneration Creative Technology Talent Pipeline


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025